Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amylyx Pharmaceuticals Inc (AMLX)
NASDAQ:AMLX
RESEARCH TOOLSreports
AMLX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.58 - $19.95
Previous CloseN/A
Volume98.90K
Average Volume (3M)905.40K
Market Cap
$305.06M
Enterprise Value-$11.21M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.81
Next Earnings
Mar 26, 2025EPS Estimate
-0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.82
Shares Outstanding85,690,720
10 Day Avg. Volume702,510
30 Day Avg. Volume905,404
Standard Deviation0.34
R-Squared0.00611
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.24
Price to Cash Flow (P/CF)-1.50
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.03
Enterprise Value/Ebitda0.05
Forecast
1Y Price Target
$11.00Price Target Upside212.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Amylyx Pharmaceuticals Inc News
PremiumCompany Announcements
Amylyx Partners with Gubra for GLP-1 Antagonist
PremiumCompany Announcements
Amylyx Pharmaceuticals Q3 2024 Financial Highlights---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe Phase 3 trial design for avexitide is based on prior successful trials and minimizes risk.
Financial StabilityAmylyx has sufficient cash into 2026 despite a net loss in 3Q25, providing a financial cushion for ongoing developments.
Bears Say
Pipeline ChallengesThe rest of Amylyx's pipeline beyond avexitide is viewed as having a relatively low probability of approval and is considered as upside for valuation.
---
Ownership Overview
13.84% Insiders
5.99% Mutual Funds
27.84% Other Institutional Investors
47.00% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AMLX FAQ
What was Amylyx Pharmaceuticals Inc’s price range in the past 12 months?
Amylyx Pharmaceuticals Inc lowest stock price was $1.57 and its highest was $19.95 in the past 12 months.
What is Amylyx Pharmaceuticals Inc’s market cap?
Amylyx Pharmaceuticals Inc’s market cap is $305.06M.
When is Amylyx Pharmaceuticals Inc’s upcoming earnings report date?
Amylyx Pharmaceuticals Inc’s upcoming earnings report date is Mar 26, 2025 which is in 33 days.
How were Amylyx Pharmaceuticals Inc’s earnings last quarter?
Amylyx Pharmaceuticals Inc released its earnings results on Nov 07, 2024. The company reported -$1.07 earnings per share for the quarter, missing the consensus estimate of -$0.704 by -$0.366.
Is Amylyx Pharmaceuticals Inc overvalued?
According to Wall Street analysts Amylyx Pharmaceuticals Inc’s price is currently Undervalued.
Does Amylyx Pharmaceuticals Inc pay dividends?
Amylyx Pharmaceuticals Inc does not currently pay dividends.
What is Amylyx Pharmaceuticals Inc’s EPS estimate?
Amylyx Pharmaceuticals Inc’s EPS estimate is -0.52.
How many shares outstanding does Amylyx Pharmaceuticals Inc have?
Amylyx Pharmaceuticals Inc has 85,690,720 shares outstanding.
What happened to Amylyx Pharmaceuticals Inc’s price movement after its last earnings report?
Amylyx Pharmaceuticals Inc reported an EPS of -$1.07 in its last earnings report, missing expectations of -$0.704. Following the earnings report the stock price went up 5.145%.
Which hedge fund is a major shareholder of Amylyx Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in AMLX
---
Amylyx Pharmaceuticals Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.00 (212.50% Upside)
$11.00 (212.50% Upside)
Blogger Sentiment
Bullish
AMLX Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $185.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 6.4%
Last 30 Days ▼ 6.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-77.83%
12-Months-Change
Fundamentals
Return on Equity
-84.43%
Trailing 12-Months
Asset Growth
-46.27%
Trailing 12-Months
Company Description
Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases.
---
AMLX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials for the company's pipeline, particularly in Wolfram syndrome and PBH, and maintained a strong financial position. However, challenges include a net loss for the quarter, FDA restrictions on a trial, and discontinued product revenues.Read More>---
AMLX Stock 12 Month Forecast
Average Price Target
$11.00
▲(212.50% Upside)
Technical Analysis
Best Analysts Covering AMLX
1 Year
1 Year Success Rate
6/18 ratings generated profit
1 Year Average Return
-17.78%
reiterated a buy rating 3 months ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -17.78% per trade.
---